Prescription by Subscription: PROMOMED Launches Russia’s First Patient-Focused Pharma Subscription Program

In celebration of its 20th anniversary, PROMOMED has become the first pharmaceutical company in Russia to launch a medication subscription program for patients undergoing course-based therapy. The initiative allows patients to access PROMOMED’s treatments at significantly reduced prices and maintain continuous therapy in a financially comfortable way.

The first phase of the program includes four key medications:

• Queensenta® – for treatment of type 2 diabetes.

• Welgia® – for management of overweight in adults.

• Enligria® – for weight loss in adults and adolescents aged 12 and older.

• Tirzetta® – for treatment of obesity and type 2 diabetes.

By subscribing to a physician-recommended treatment course, patients benefit from structured medication use, convenient reminder services, and considerable cost savings. The program is designed to help individuals complete their treatment without interruptions, improving outcomes and adherence.

Alexander Efremov, CEO of PROMOMED, commented:

“Public health and life expectancy are closely linked to the accessibility of modern, high-quality medications. But even when such therapies are available, treatment success depends largely on patient adherence to prescribed regimens — what we call treatment compliance.”

“Having carefully analyzed the market, common prescription patterns, and physician-recommended treatment protocols for our medicines, we developed Russia’s first-ever pharmaceutical subscription model for course-based therapies.”

“This approach can help patients save up to 40% on treatment costs. More importantly, it enables consistent access to medication, which is critical in managing complex and potentially life-threatening conditions like diabetes and obesity.”

Patients can subscribe and purchase medications via the following link:
PROMOMED Subscription Program